Apogee therapeutics, inc.APGE.US Overview
APGE Overall Performance
APGE AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
APGE Current Performance
2.52%
Apogee therapeutics, inc.
1.06%
Avg of Sector
0.41%
S&P500
APGE Key Information
APGE Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
APGE Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
APGE Profile
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Price of APGE
APGE FAQ
When is APGE's latest earnings report released?
The most recent financial report for Apogee therapeutics, inc. (APGE) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APGE's short-term business performance and financial health. For the latest updates on APGE's earnings releases, visit this page regularly.
How much debt does APGE have?
As of the end of the reporting period, Apogee therapeutics, inc. (APGE) had total debt of 10.85M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does APGE have?
At the end of the period, Apogee therapeutics, inc. (APGE) held Total Cash and Cash Equivalents of 124.19M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is APGE's EPS continuing to grow?
According to the past four quarterly reports, Apogee therapeutics, inc. (APGE)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of APGE?
Apogee therapeutics, inc. (APGE)'s Free Cash Flow (FCF) for the period is -62.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 113.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.